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Abstract: Background: Osteonecrosis (ON) of the femoral head represents a potentially severe disease
of the hip where the lack of bone regeneration may lead to femoral head collapse and secondary
osteoarthritis, with serious pain and disability. The aim of this European, multicentric clinical trial
was to prove safety and early efficacy to heal early femoral head ON in patients through minimally
invasive surgical implantation of autologous mesenchymal stromal cells (MSC) expanded from
bone marrow (BM) under good manufacturing practices (GMP). Methods: Twenty-two patients with
femoral head ON (up to ARCO 2C) were recruited and surgically treated in France, Germany, Italy
and Spain with BM-derived, expanded autologous MSC (total dose 140 million MSC in 7 mL). The
investigational advanced therapy medicinal product (ATMP) was expanded from BM under the
same protocol in all four countries and approved by each National Competent Authority. Patients
were followed during two years for safety, based on adverse events, and for efficacy, based on clinical
assessment (pain and hip score) and imaging (X-rays and MRIs). Patients were also reviewed after
5 to 6 years at latest follow-up for final outcome. Results: No severe adverse event was recalled as
related to the ATMP. At 12 months, 16/20 per protocol and 16/22 under intention-to-treat (2 drop-out
at 3 and 5 months) maintained head sphericity and showed bone regeneration. Of the 4 hips with
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ON progression, 3 required total hip replacement (THR). At 5 years, one patient (healed at 2 years
visit) was not located, and 16/21 showed no progression or THR, 4/21 had received THR (all in the
first year) and 1 had progressed one stage without THR. Conclusions: Expanded MSCs implantation
was safe. Early efficacy was confirmed in 80% of cases under protocol at 2 years. At 5 years, the
overall results were maintained and 19% converted to THR, all in the first year.
Keywords: femoral head osteonecrosis; bone regeneration; expanded MSC; clinical trial
1. Introduction
Osteonecrosis (ON) of the femoral head, whether idiopathic or secondary to alco-
holism, steroids, sickle cells or other conditions, is a devastating health problem with no
current cure. The established necrosis of the femoral head bone may progress to head
collapse with serious pain and functional limitation. Its pathophysiology includes femoral
head destruction followed by reparative processes in the periphery of the necrotic area [1].
Despite some spontaneous bone regeneration in a mineralization front that isolates the
necrotic area, bone resorption initiates the subchondral fracture that may lead to femoral
head collapse [2]. In the early phases of this condition, while the femoral head sphericity
is maintained, different treatments have been proposed, with variable effectiveness [3] to
enhance bone regeneration, trying to avoid head collapse [4]. Total hip replacement (THR)
is currently increasing not only as a final treatment but at any stage [5], even in the young
patient, with obvious disadvantages specially at early ages.
Treatment of early osteonecrosis stages is initially based in a drill or forage into the necrotic
area of the femoral head, with limited effectiveness except in early ON stages [6,7]. Although
originally this forage was considered a means of releasing high pressure within the bone
compartment (core decompression), it has evolved into a transosseus pathway to reach the
necrotic area of the femoral head and deliver biotechnology and regenerative agents [8].
The development of alternative solutions to enhance healing through bone regenera-
tion is a challenging aim. Although, overall, regenerative medicine techniques (including
mesenchymal stem cell (MSC) implantation in the osteonecrotic area, and others such as
intra-arterial infiltration with MSC, implantation of bioactive molecules, or even platelet-
rich plasma) are seen as a means to avoid THR [9], the most suitable patients and the most
appropriate procedures are still unclear.
Medicaments based on culture-expanded autologous mesenchymal stromal cells
(MSC) may fulfil the aim of delivering a high number of cells, capable of generating
new bone [10], with a potential role in osteoinduction and osteogenesis within the os-
teonecrotic femoral head. Early clinical data supporting expanded MSC implantation [11]
unfortunately lack validated Good Manufacturing Practices (GMP) procedures [12] and
appropriate quality controls to confirm safety and reproducibility of the cell medicament
production and transportation [13]. Unless these data are offered to grant the regulatory
approval, clinical application may not be accepted.
In this context, a European consortium designed this multicentric clinical trial with
the primary aim of assessing the safety of expanded autologous bone-marrow-derived
MSC (BM-MSC) implanted through forage into the femoral head. A secondary aim was
set in the evaluation of efficacy to obtain bone healing in patients with early osteonecrosis
of the femoral head at 1 and 2 years. To gain clinical relevance, we spread the aim of this
clinical trial to also report in this paper the efficacy evaluation after 5 years.
2. Methods
2.1. Study Design and Participants
A phase I/IIa open, prospective, multicentric, interventional clinical trial named
ORTHO2 in the REBORNE EU-funded project (Regenerating Bone defects using New
biomedical Engineering approaches, FP7 HEALTH-2009-1.4-2, Grant Agreement 241879)
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was designed to evaluate safety and feasibility in five European centres from four countries,
with total recruitment of 26 patients, 22 of whom received treatment (Figure 1, CONSORT
diagram) from March 2014 to June 2015.
Figure 1. CONSORT diagram of the ORTHO2 clinical trial. ON: Osteonecrosis; BM: Bone Marrow; IMP: Investigational
Medical Product; hMSC: Human Mesenchymal Stems Cells (expanded).
The inclusion criteria were age 18 to 65, both sexes, with symptomatic osteonecrosis
of the femoral head, with less than 6 months of evolution, in patients that signed informed
consent being able to provide it and able to understand and accept the study constraints,
having medical health care coverage in any of the participating countries.
The exclusion criteria were pregnancy, breastfeeding women and women who are
of childbearing age and not practising adequate birth control; participation in another
therapeutic trial in the previous 3 months; stages 3 (III) or more (Arlet and Ficat, ARCO,
Steinberg) of severe femoral head osteonecrosis, primarily based on diagnosis by imaging
(X-rays, MRI); flattening or collapse of the femoral head (Arlet and Ficat 4, ARCO IV, Stein-
berg stage IV and beyond) or articular cartilage collapse at the time of core decompression
surgery; septic arthritis; stress fracture; non-osteonecrosis metabolic bone diseases (par-
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ticularly Paget’s disease of bone, osteogenesis imperfecta, primary hyperparathyroidism,
fibrous dysplasia monostotic, polyostotic (McCune–Albright syndrome) and osteopetrosis);
any active bisphosphonate treatment or any history of intravenous bisphosphonate treat-
ment; history of prior or concurrent diagnosis of HIV-, hepatitis-B- or hepatitis-C-infection
(confirmed by serology or PCR); active hepatitis B or hepatitis C infection at the time of
screening; known allergies to products involved in the production process of MSC; acute
and persistent chronic bacterial infections such as brucellosis, typhus, leprosy, relapsing
fever, melioidosis and tularaemia; history of neoplasia or current neoplasia in any organ;
corticoid or immunosuppressive therapy more than one week in the two months before
study inclusion; patients who will require continuous, systemic, high-dose corticosteroid
therapy (more than 7.5 mg/day) within 6 months after surgery; patients who are in active
treatment for cancer or blood dyscrasia, or have received chemotherapy, radiotherapy or
immunotherapy in the past 2 years; history of regular alcohol consumption exceeding
2 drinks/day (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within
6 months of screening and/or history of illicit drug use; serum AST (SGOT)/ALT (SGPT)
> 2.5 × (institutional standard range); MRI-incompatible internal devices (pacemakers,
aneurysm clips, etc.); body mass index (BMI) of 40 kg/m2 or greater; patients unable to
tolerate general anaesthesia; insulin-dependent diabetes; patients with poorly controlled
diabetes mellitus (HbA1C > 8%), or with peripheral neuropathy, or known concomitant
vascular problems; patients receiving treatment with hematopoietic growth factors or
anti-vasculogenesis or anti-angiogenesis treatment; traumatic osteonecrosis; adult in the
care of a guardian (subject legally protected); or impossibility to meet at the appointments
for the clinical follow-up.
The anonymous clinical data and imaging of the eligible patient were forwarded to
the other clinical centres. Each patient was only included if no centre was against inclusion
and at least two more centres agreed on the inclusion and the treatment.
To further standardize the inclusion, patients to be included were those who, alterna-
tively, would have received forage, thus avoiding (excluding) patients with head collapse
or sphericity loss to be treated with other reconstruction techniques.
As shown in the CONSORT diagram (Figure 1), 26 patients were recruited, one of
them excluded before bone marrow extraction as hepatitis B virus-positive serology was
confirmed. Three more were excluded before surgery, two due to the fact that the number
of expanded cells did not achieve the required concentration, and one due to contamination
of the investigational product.
Of the 22 treated patients and analysed under ITT (intention-to-treat), two of them
caused early drop-out, the first one was imprisoned (at three months after surgery), and
the second one was treated in another centre (at five months by the patient’s decision to
undergo Total Hip Replacement).
Among the 22 treated patients, 1 case received treatment with a protocol deviation due
to overgrowth of cells that required early release and implantation of the Investigational
Medical Product (IMP) before Standard Operating Procedure (SOP) specification (15 days
post bone marrow extraction, instead of 21 days).
The efficacy follow-up was performed at 12 months, and the safety follow-up at
24 months. Intermediate results were evaluated at three and six months. This communica-
tion also shows a late follow-up of 5 to 6 years.
A total of 22 patients were evaluated at three months, a total of 21 were analysed
at six months and 12 months on ITT, and a total of 17 patients underwent follow-up at
5 to 6 years.
Table 1 summarizes the demographics and characteristics of the disease. The mean age
of the recruited patients was 43 years with a higher proportion of males (86%), with a mean
Body Mass Index of 25, and a median ASA classification of II (63%). The principal cause of
ON was idiopathic (50%), followed by corticosteroid treatment (22%). Sixty-eight percent
of the affected femoral heads were classified as ARCO IIA, and the main evolution of ON
prior to treatment was 2.3 ± 2.2 months. No statistically significant differences between
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cases that did not heal (progression and/or THR) and those that healed were observed in the
baseline, in terms of age (t-test = 0.471), BMI (t-test p = 0.658), sex (Fisher’s test p = 0.905),
ASA classification (Fisher’s exact tests p = 0.247), alcohol consumption history (Fisher’s
exact tests p = 0.477), smoking habit history (Fisher’s exact tests p = 0.500), etiology of ON
(Fisher’s exact test p = 0.623), time of ON evolution (Mann–Whitney test p = 0.749), ARCO
classification (Fisher’s exact test p = 0.132), preoperative loss of bone (Fisher’s exact test
p = 0.470), Total Harris Hip Score (HHS) (Mann–Whitney test p = 0.783), spontaneous pain
(Mann–Whitney test p = 0.106), and weight-bearing pain (Mann–Whitney test p = 0.152).






Age (years) 43.1 10.9 21.0 62.0
Height (cm) 173.7 8.7 152 190
Weight (Kg) 77.4 20.0 50 118
BMI 25.7 5.6 17.3 36.8





Alcohol history (yes) 7 32%
No. drinks per day 1 2.2 1.9 1 6
Duration (years) 2 12.8 6.9 2 20
History of smoking (yes) 11 50%
No. packs per day 1.1 0.7 0.2 2
Duration (years) 3 19.8 8.8 5 30
Months since diagnosis of ONFH 4 2.3 2.2 0.1 7.6
Cause of ONFH:
Alcohol consumption 1 4.5%
Corticosteroids 5 22.7%
Idiopathic 11 50.0%
Other 5 5 22.7%
Description of the affected femur





Loss of bone in AP X-ray (none) 6 18 82%
Preoperative clinical data
Total Harris Hip Score 63.0 19.0 40 91
Spontaneous pain in VAS scale (mm) 7 30.3 20.5 1 76
Weight-bearing pain in VAS scale (mm) 8 57.9 21.1 10 100
ONFH: Osteonecrosis of the Femoral Head; VAS: Visual Analogue Scale; 1 One drink corresponds to 150 mL of
wine or 360 mL of beer or 45 mL of hard liquor.; 2 One case stopped drinking 11 years ago; 3 Three cases reported
being former smokers since 1, 6 and 7 years.; 4 Median (P25/P75) = 1.5 (0.5/3.4) months; 5 Alcohol+Corticosteroid
(n = 1) Sickle cell disease (n = 2), Thalassemia (n = 1), Octreotide treatment (n = 1); 6 Four cases reported a
loss of bone minor than 50% of diameter; 7 Median (P25/P75) = 29.5 (17.0/41.2) months; 8 Median (P25/P75) =
60.0 (48.0/70.0) months.
Sphericity was observed at inclusion in all recruited cases. No history of drug con-
sumption was declared. At the recruitment visit, one patient had a history of immunosup-
pressive treatment, and eight patients had had occasional corticosteroid treatment, neither
interpreted as the cause of ON.
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2.2. Study Authorization and Declaration
Four Ethics Committees (EC) of clinical research in the four participating countries
(Person Protection Committee (Comité de Protection des Personnes CPP) Tours Région
Centre Ouest 1, Tours, France; La Paz Hospital Ethics Committee for Clinical Research
(Comité de Ética de la Investigación clínica CEIC), Madrid, Spain; Ulm University Ethics
Committee, Ulm, Germany; and Istituto Ortopedico Rizzoli Ethics Committee, Bologna,
Italy) approved the protocol and related documents for all participating clinical centres.
The Ethics Committee at La Paz Hospital, the coordinator centre, gave the final approval
on 24 June 2013, with hospital code 3875. As the investigational medicinal product (IMP)
was an Advanced Therapy Medicinal Product (ATMP) for human use, the responsibility
to authorize the trial relies on the National Competent Authorities (NCA), following the
European Voluntary Harmonization Procedure (VHP, VHP201332). The authorizations
were obtained in all participating countries between January and March 2013. The sponsor
of the study was the Autonomous University of Madrid, Madrid, Spain. The EudraCT
number of the trial was 2012-002010-39 and the trial was also incorporated into the database
ClinicalTrials.gov with the identifier NCT02065167.
2.3. Procedures
2.3.1. Bone Marrow Harvesting
The donation, procurement and testing of the BM were performed in compliance with
the Cells and Tissues Directives; in particular, according to the requirements laid down
in Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the
European Parliament and of the Council as regards certain technical requirements for the
donation, procurement and testing of human tissues and cells, and applicable national laws.
Specifically, patients needed to be negative in serology for Anti-HIV 1-2 Ab, Anti-HCV Ab,
HBs Ag, Anti-HBc Syphilis, and negative (not detected by PCR) in HIV NAT, HCV NAT, or
HBV NAT. The bone marrow cells were harvested in the operating room under anaesthesia,
from the posterior iliac crest, through percutaneous bone puncture. Bone marrow was
harvested by fractions of 2–4 mL in 20 mL syringes prefilled with heparin, then transferred
into a transportation bag, and labelled according to the approved protocol. The harvest, in
its primary packaging, was laid out in an isothermal box labelled according to Directive
2004/23/EC and 2006/17/EC. The transport was done between 18 ◦C and 24 ◦C if less
than 30 min, and at 4 ◦C with temperature traceability if the transportation time was longer
than 30 min.
2.3.2. Cell Product Manufacturing Process in GMP Facilities
An aliquot of the starting material was removed to carry out controls, including cell
count, viability, CFU-F-assay, and sterility. The entire manufacturing process was per-
formed at each manufacturing site, following the same procedure described in ORTHO-1
CT (EudraCT 2011-005441-13) and ORTHOUNION CT (EudraCT 2015-000431-32) [14,15].
In brief, the culture was performed when the received BM, without any further manip-
ulation, was seeded in alpha-MEM medium with 5% PL and 1 I.U./mL heparin, at the
concentration of 50.000 WBC/cm2, in a culture chamber. The culture chambers were placed
in incubators (5% CO2 atmosphere, 95% relative humidity at 37 ◦C). After 72 h, the su-
pernatant was discarded and replaced by fresh complete medium (alpha-MEM with 5%
PL). At day +7 and +10 of culture, the supernatant was again discarded and replaced by
complete medium. At +14 day, the confluence was evaluated and if >50%, the cells were
washed with phosphate buffered saline (PBS), detached and harvested using trypsin. If cell
confluence was lower than 50%, an additional medium exchange was performed, and cells
were harvested at day 17. The harvested cells were then re-seeded at the concentration of
4 × 103 MSC per cm2 in new culture chambers in alpha-MEM medium with 8% PL. An-
other medium exchange was performed at day 17. At day 21, the cell culture was washed
with PBS and the cells detached and harvested using trypsin. The final product resulting in
ORTHO-2 BM-MSC was the active substance on which quality controls were applied. The
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active substance was resuspended in an albumin solution to obtain the ORTHO-2 BM-MSC
tissue-engineered product. Cells were packaged for the shipment to the operating room in
1 syringe of 7 mL, at a dose of 20 million cells per mL (total of 140 million cells). All the
materials and reagents were selected and validated to ascertain their compliance to be used
in the manufacturing process, with certificates of analysis of key components included in
the investigational medicinal product (IMP) for which approval was obtained at each of
the NCA of the participating countries (France, Germany, Italy, Spain).
The cell expansion process and the delivered final cell product is described in Table 2,
including data from the bone marrow aspiration, at seeding, reseeding at P0, reseeding at
P1, and product release criteria. The achieved standardization of the cell product can be
observed in Table 2.
Table 2. Cell expansion and final cell product.
Mean SD Min Max
BM aspiration
Aspirated bone marrow volume 51.20 8.80 31.50 65.00
Cell count WBC/mL BM aspirate (×107) 2.07 11.40 11.20 61.00
CFU-F of BM/×106 WBC 45 53 0 190
Doubling time and population doubling
in p0 and p1 of expansion
Doubling time in P0 (h) 23.80 3.30 12.40 28.20
Doubling time in P1 (h) 54.80 31.50 22.10 186.00
Number if population doublings in P0 14.60 3.00 12.40 27.10
Number if population doublings in P1 3.20 1.20 0.90 6.50
Cumulative population 17.70 3.40 13.80 30.00
Yield
MSC/ul BM aspirate in P0 (×103) 8.46 10.80 0.24 51.00
MSC/ul BM aspirate in P1 (×104)z 6.90 9.31 0.21 35.20
Overall harvest (×108) 2.87 1.87 0.42 7.38
Identity: Surface markets after P1
%CD34 positive cells 0.29 0.26 −0.09 1.30
%CD45 positive cells 0.49 1.14 0.00 5.40
%CD73 positive cells 97.81 4.77 78.00 100.00
%CD90 positive cells 99.30 0.49 93.20 100.00
%CD105 positive cells 97.38 4.20 82.40 100.00
%MHC cII positive cells 3.62 7.01 0.00 27.60
Viability
% Viable cells in aspirate 95.37 3.20 89.40 99.99
% Viable cells after P0 94.92 4.70 82.70 100.00
% Viable cells after P1 96.29 2.82 88.30 99.90
Microbial safety: 100% of endotoxin tests and 100% of mycoplasma tests at P1 were
negative (n = 10). Microbial tests were negative (n = 25) in BM samples (100%), in ex-
panded cells at P0 (96%) and expanded cells at P1 (100%). The production process of the
contaminated sample identified at P0 was stopped and material destroyed.
2.3.3. Cell Product
The IMP was composed of mesenchymal stromal cells (MSC) obtained through a man-
ufacturing process based on plastic adherence and expanded in culture using 5% human
donor platelet lysate produced in Ulm (Germany) and distributed to the other cell therapy
units, according to a culture method developed by the REBORNE consortium. MSCs
were defined by a specific immunophenotype (CD 45−/90+/105+/73+/HLA-DR) [16]
with demonstrated osteogenic properties in vitro and in vivo. The IMP manufacturing
authorization was granted to all five participating GMP facilities (Établissement Français
du Sang (EFS) at Créteil and Toulouse, in France; Transfusion Medicine Institute of Ulm in
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Germany; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milano in Italy;
and Cell Production Unit at Hospital Puerta de Hierro-Majadahonda of Madrid in Spain).
Each batch of the final product was tested for cell content, immunophenotype, sterility,
endotoxins, and Mycoplasm before release. Additional quality controls were performed
according to each country-specific national competent requests. Descriptive cell values,
along the process of expansion and at the release of the cell product in the treated cases,
are included in Table 2. A suitable mode of transportation ensured the delivery of the BM
package to the manufacturing site and of the cells from the GMP facility to the surgical
room within 18 h, and the process was validated for cell viability [10,13].
2.3.4. Surgical Procedure
As with any other implant in Orthopaedic surgery and to avoid any risk of bacteraemia,
antibiotic prophylaxis according to the protocol of each hospital (such as cephazolin 1 g
iv preoperative) was performed prior to the procedure. After anaesthesia, patients were
positioned supine on a fracture table under sufficient traction to maintain the patient lower
limbs. A radiological C-arm was placed and both AP and axial views of the femoral head
and neck were checked under fluoroscopy.
The surgical approach was minimally invasive lateral to the proximal femur. A guide
wire was drilled from the lateral cortex of the subtrochanteric femur into the femoral
head lesion, under fluoroscopic AP and axial control. Then, a 4 mm cannulated drill was
introduced along the drilling guide into the femoral head (there was no notification of
femoral head cartilage perforation by drilling). The cells (140 million cells suspended in
7 mL) were injected directly in the forage tunnel in a single administration. Drains were
not used in this procedure.
2.4. Outcomes
2.4.1. Safety
A primary safety endpoint, defined as detection of local and general complications,
was fixed for the clinical trial at any time in the 24 months of follow-up; adverse event (AE)
reporting at 3, 6 and 12 months; severe adverse event (SAE) and suspected unexpected
and serious adverse reactions (SUSAR) reporting at any time, as required by the regulatory
frame (to Eudravigilance (European Union Pharmacovigilance database), to the National
Competent Authorities and the Ethics Committees).
2.4.2. Efficacy
The efficacy was defined as bone healing, without increasing the complication rate,
of early osteonecrosis treated through a standard-of-care core decompression procedure
plus a percutaneous injection of autologous stem cells, derived from bone marrow and
expanded under GMP conditions. Non-healing was defined as radiological (X-ray or MRI)
progression to a higher stage and/or undergoing Total Hip Replacement (THR).
Radiological progression on X-ray (anteroposterior and lateral views) was evaluated
at 3, 6 and 12 months, and on MRI (coronal and transversal view) at 3 and 6 months. The
long-term radiological progression was assessed on X-rays at 5 to 6 years. Clinical healing
was considered when the pain was under the threshold of 30 (out of 100 in a Visual Analog
Scale (VAS)) [17], and the imaging studies did not show any progression or collapse of the
femoral head.
2.5. Statistical Analysis
Descriptive statistics and Fisher’s exact test or Mann–Whitney test were used to
compare categorical and continue baseline variables. Comparison of means was performed
with paired Student’s t-test between follow-up visits for pain and Harris Hip Score variables.
A generalized estimating equation (GEE) with logit link function was conducted to evaluate
the risk factors of ON-progression or THR. The statistical significance was defined with 95%
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of confidence (p ≤ 0.05). Data were analysed using STATA software version 12 (StataCorp.,
College Station, TX, USA).
3. Results
3.1. Safety Endpoint
No Adverse Event (AE), or Serious Adverse Event (SAE), or Suspected Serious Ad-
verse Reactions (SUSAR), were identified as related with the IMP. Particularly, no tumorous
condition or cell-related overgrowth was detected in any patient after cell implantation. A
total of 4 SAEs were communicated, unrelated to IMP, and requiring inpatient admission
and treatment. The first SAE was in a 43-year-old female, with one year of evolution
intermediate thalassemia, who presented with deep venous thrombosis one month after
surgery, for a reported duration of 25 days. The second SAE was in a 48-year-old male
who presented with contralateral femur fracture 3 months after surgery while playing
volleyball. He was treated by open reduction and internal fixation, discharged two days
after fracture surgery, and fully recovered without sequelae. The third SAE occurred in
a 34-year-old male, admitted 8 months after the index operation due to acute arthritis,
received antibiotics despite negative cultures, and resolved after THR due to persistent
pain, thus being considered a non-healed case. The fourth SAE occurred in a 45-year-old
male who required hospital admittance due to upper gastrointestinal bleeding, 12 months
after surgery, that fully resolved at 3 days. Reported AEs included persistent pain, pain
and limping, and pain at the contralateral leg.
3.2. Efficacy Endpoint and Follow-Up
Mean preoperative spontaneous pain was 30.3 ± 20.5 mm on theVAS scale, and
changed to 15.4 ± 18.1 mm at three months of FU (paired t-test p = 0.018), to 15.3 ± 26.3 mm
at 6 months of FU (paired t-test p = 0.013), and to 9.5 ± 17.8 mm at 12 months of FU (paired
t-test p = 0.001). Mean preoperative weight-bearing pain was 57.9 ± 21.1 mm on the VAS
scale, and changed to 30.5 ± 24.2 mm at three months of FU (paired t-test p = 0.018),
to 32.8 ± 31.6 mm at 6 months of FU (paired t-test p = 0.013), and to 26.0 ± 21.3 mm
at 12 months of FU (paired t-test p = 0.014). Total Harris Hip Score improved a total of
19.6 ± 16.8 points from preoperative to 12 months FU, which was statistically significant
(paired t-test p = 0.008).
Clinical and radiological regeneration (Figure 2), with maintained head sphericity,
was observed in 80% of the treated patients (16/20) after a one-year follow-up, 73% (16/22)
on ITT (including 2 drop-out cases only evaluated at 3 months). Four cases progressed to
the next stage of ON (4/20), and of these, 3 received THR. Generalized estimating equation
analysis (model adjustment: Wald Chi-square = 177.35; p = 0.001) for pain higher than
30/100, age higher than 50, time since diagnosis higher than 3 months, positive alcohol
consumption, and positive smoking habit, only showed a significant interaction of ON
progression/THR with pain (OR = 3.8 [3.0–4.7]; p = 0.001).
After 5 to 6 years of follow-up, neither other case had progressed to the next stage of
ON nor received another THR. We investigated 22 cases, including drop-out cases. One
patient was not located at 5 years and was lost after completing the 2-year FU in the trial
but was considered healed at 2 years. Of the remaining 21 cases, we observed that 16/21
were healed and maintained their femoral head at 5 years, 1 had progressed to the next
ON stage in the first year of treatment but required no THR at 5 years, 4 cases in total
had received THR (including one of the drop-out cases), all in the first year after surgery.
Details of the case progression are described in Figure 3.
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Figure 2. T1 MRI of the femoral head, coronal section through the ON area; (a) preoperative, (b)
6 months after delivering the cells.
Figure 3. Late follow-up of ORTHO2 patients (last update, January 2020): One case with early
progression to the next stage without collapse after five years (case 105). Three cases of THR during
the first year of the clinical trial (cases 203, 312, 502). One case drop-out at 3 months (case 307),
healing confirmed at 5 years. One case drop-out at 5 months (case 602), underwent THR in the first
year. One case healed at 2 years (case 501), lost to follow-up at 5 years.
4. Discussion
The main result of this study is that bone regeneration in the femoral head can be safely
obtained with autologous expanded MSCs from bone marrow at a dose of 140 million
MSCs, injected into the femoral head through a minimally invasive approach after forage.
This confirms findings in many other reports and reviews about cell therapy to regenerate
bone with expanded [18] or concentrated MSCs [9,19,20].
Regarding the efficacy outcome, the literature on MSCs to treat early ON offers ranges
of 70–90% avoidance of collapse and/or THR at 2 to 5 years, and even 30 years [8,9,19–21].
Different sources of variability have been identified, related to patients, diagnosis, and
treatment. All our cases were acute (under 8 months of evolution since the onset of the
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disease), and treatment was not performed on established long-term osteonecrosis. Late
treatment after the ON onset may have encountered spontaneous repair in the periphery
of the necrosis, preventing the collapse [1], which may be unrelated to the treatment under
study. Although seldom reported, the onset of the ON lesion under treatment should be
clarified to compare the outcome of different ON treatments and series. Another source of
variable outcome is the ON aetiology, as corticosteroid-related ON (5/22 in our trial) may
associate less locally available osteoprogenitors [22], and the cellular reservoir is unclear
in other forms of ON, particularly if idiopathic. The indication of THR also incorporates
variability into the outcome, as patients may request early THR even if no head collapse has
occurred but if persistent early pain is not controlled. Surgical indication of THR may vary
centre to centre, and restrictive THR indication was identified as a cause of one early drop-
out that received THR in a different centre after leaving the study, without documented
head collapse. Of note, all THRs were performed in the first year after MSC treatment,
thus confirming that bone regeneration, when obtained, was stable and successfully healed
patients that would not require any other operation at least in 5 years. Instead, other studies
showed an increasing number of THRs along the 5 years follow-up [23], which may relate
to less efficacious regeneration, prompting some researchers to advocate biomechanical
augmentation instead of cell therapy alone [24].
Bone regeneration was observed in all our cases after receiving the expanded cells,
even if THR was required in 19% of the cases at 5 years (3/22 received THR in the trial,
plus one more THR in an early drop-out). Other studies have shown that 70% of the
asymptomatic hips with no treatment became either symptomatic (38%) or collapsed
(32%) after 5 years or more [25]. Besides, forage alone may be effective to decrease pain
immediately after surgery [26], but not to avoid THR in almost half of the cases in stage II
ON [6,27]. Results with bone marrow concentration injected through the forage in early ON
stages favorably compared with forage alone [28–30], although this may change depending
on the technique and the patient [27]. Taken together, the success rate of Bone Marrow
Concentrate (BMC) injection after forage, compared with forage alone, is confirmed in
clinical scoring, head collapse and THR conversion, through a meta-analysis of the available
trials [20], although serious variability and risk of bias were also detected.
The question remains whether expanded MSC can perform better and more pre-
dictably than BMC. However, data on expanded MSC are scarce [11,31]. A dose of 2 × 106
expanded cells was considered to control the progression of 51/53 injected hips at 5 years
versus 27/44 (with 7 lost to FU) hips after forage [11], which can be considered encourag-
ing results. Unfortunately, the expansion procedure, quality controls and trial procedure
are unclear in early reports [11]. As an augmentation of tricortical iliac bone graft with
vascular pedicle and biomaterial, expanded MSC were implanted in another study at a
dose of 0.5–1 × 108 [31]. Cells were not expanded under GMP criteria and were frozen
and thawed before implantation. While no progression was observed at 2 years in 7 out of
9 hips with ON stage III, the real effect of cells is unclear [31]. In our study with 140 × 106
expanded MSCs, 3 THR and 1 progression in the ON stage were identified out of 20 cases, but
no progression was seen after 12 months until the latest follow-up of minimum 5 years.
Pain and clinical scoring were significantly improved by the technique, and therefore
can be seen as a significant predictor of failure (progression and/or THR), although our
limited number of patients may require further confirmation. Unfortunately, pain was not
controlled and/or osteonecrosis progression was not necessarily stopped by the obtained
bone regeneration in those failed cases. Neither time since diagnosis nor alcohol consump-
tion, smoking habit, or age showed any association with ON progression in our study.
Therefore, other aspects may influence the early progression to head collapse, possibly
including the amount, timing, and location of the obtained bone regeneration. It is unclear
if those aspects may relate to the disease, the patient, or the surgery characteristics. Further
studies are required to clarify if the disease aetiology, the patient regenerative potential or
the surgical technique may be at the origin of this progression.
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Remarkable aspects in the study include the clinical use of a high dose of expanded
autologous MSC (140-million cells total dose), higher than other reported trials. Inter-
estingly, a cell dose of 1 × 108 (100 million cells) has been defined in a meta-analysis as
a threshold for better effects on disease progression [32]. This dose safely obtained the
clinical and radiological healing of femoral head in our study, both in males and females,
despite the limited number of cases in such an early trial. The relationship between dose
and healing success has been previously proven with bone marrow concentrate [33], and
this is probably also the case with expanded cells.
The first limitation of the study is the design, while a comparative, randomized
study would offer higher evidence. However, strength of the design is the multicentric,
multinational set-up of the clinical trial that validates the approach and the development of
a consistent expanded-cell medication in different settings. Also, the long follow-up (at least
5 years) is a strength of the current study, as it is rare in a complex clinical trial on this kind
of treatment. Another potential limitation is the variability related to the origin and cause
of ON, and to the patient, as the trial evaluates an autologous treatment with a different
osteogenic potential of individual patients. However, the stringent inclusion/exclusion
criteria support the study validity and relevance. Also, a limitation relates to the difficult
endpoint of efficacy, here defined as ON progression, eventually to collapse, and/or THR.
Timely bone regeneration in a sufficient amount to avoid progression depends not only
on the cells but also on the status of the disease and the implanted femoral head, while
THR indication also depends on the patient tolerance to pain. Therefore, other means of
calculating efficacy may be required.
5. Conclusions
We showed in a multicentric interventional trial that the administration of high-dose
MSCs, expanded from autologous bone marrow, was safe and capable of producing bone
regeneration in all studied cases at 3 and 6 months. Also, maintenance of femoral head
sphericity was confirmed per protocol in 16/20 (80%) of treated hips at one year. Finally, a
minimum 5 years follow-up, including early drop-outs, could confirm that no THR or ON
stage progression was detected after 12 months, and head sphericity was maintained in
16/21 cases at 5 years.
Although a definite proof of efficacy would require a randomized trial, we controlled
and highlighted different crucial issues, such as disease variability (only acute and subacute
cases were recruited), osteogenic potential (unclear differences due to autologous origin),
THR indication (restricted indication if no collapse), and we provided long-term follow-up
to clarify whether the ON was successfully healed.
Author Contributions: Conceptualization, E.G.B., P.R., P.H., N.B.; methodology, E.G.B., N.G.P.E.,
P.R., P.H., N.B., G.C., R.M.G.D., C.A.S., H.R., R.G., M.D., H.S., P.L.; validation, E.G.B., N.G.P.E., P.R.,
P.H., N.B.; formal analysis, E.G.B., N.G.P.E.; investigation, E.G.B., P.R., P.H., N.B., G.C., R.M.G.D.,
H.R., R.G., H.S. (note that the below added researchers from the REBORNE Consortium were also
heavily involved in the research); data curation, E.G.B., N.G.P.E., C.A.S.; writing—original draft
preparation, E.G.B., N.G.P.E.; writing—review and editing, ALL; project administration, E.G.B., P.R.,
P.H., R.M.G.D., C.A.S., H.R., R.G., H.S., P.L.; funding acquisition, P.L. All authors have read and
agreed to the published version of the manuscript.
Funding: The research leading to these results has received funding from the European Research
Council under the European Union’s Seventh Framework Programme (FP7/FP7-HEALTH-2009):
REBORNE Project, Grant Agreement 241876. Work in EFS and stromalab was also supported by the
Agence Nationale pour la Recherche for support of the national infrastructure: “ECELLFRANCE.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki and approved by the Ethics Committees of all participating Institu-
tions (as stated in the text, Methods section). Furthermore, the National Competent Authorities
of all participating countries approved the use of this ATMP in this protocol (see Methods section
for details).
J. Clin. Med. 2021, 10, 508 13 of 14
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: Anonymized data available on request due to ethical restrictions.
Acknowledgments: Contributing researchers from the REBORNE Consortium: Eduardo García-Rey
and Marta Dominguez-García (Servicio de Cirugía Ortopédica y Traumatología, Hospital Universi-
tario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain);
José Cordero-Ampuero (Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario
La Princesa and Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain); Julien
Stanovici (Service de Chirurgie Orthopédique et Traumatologique, Hôpital Trousseau, Université
François-Rabelais de Tours, CHU de Tours, Tours, France); Nathalie Chevallier and Alexandre
Poignard (Orthopaedic Department, Hôpital Henri Mondor, InsermU955 and UPEC, University
Paris-Est, Créteil, France); Davide Maria Donati and Benedetta Spazzoli (Orthopedic Oncology, IR-
CCS Istituto Ortopedico Rizzoli, Bologna, Italy); Manuel-Nicolás Fernandez and José-Rafael Cabrera
(Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, and Universidad
Autónoma de Madrid, Madrid, Spain); Tiziana Montemurro, Cristiana Lavazza and Elisa Monte-
latici (Laboratory of Regenerative Medicine—Cell Factory, Transfusion Center, Fondazione IRCCS
Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy); Elena Veronesi (Laboratory of Cellular
Therapies, Department of Medical and Surgical Sciences for Children & Adults, University—Hospital
of Modena and Reggio Emilia, Modena, Italy); Markus Thomas Rojewski and Ramin Lotfi (In-
stitut for Transfusion Medicine, Ulm University, and Institute for Clinical Transfusion Medicine
and Immunogenetics Ulm, German Red Cross Blood Transfusion Service and University Hospi-
tal Ulm, Ulm, Germany); Sandrine Fleury and Luc Sensebé† (L. Sensebé, deceased; STROMALab,
UMR5273-INSERM U1031, Toulouse, France); Torsten Kluba and Sebastian Scheidt (Klinik für Or-
thopädie, UniversitätsKlinikum Tübingen, Tübingen, Germany); Carmen Panaitescu Bunu (Victor
Babes University of Medicine and Pharmacy, Timisoara, Romania).
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
References
1. Takao, M.; Nishii, T.; Sakai, T.; Yoshikawa, H.; Sugano, N. Repair in osteonecrosis of the femoral head: MR imaging features at
long-term follow-up. Clin. Rheumatol. 2010, 29, 841–848. [CrossRef]
2. Hamada, H.; Takao, M.; Sakai, T.; Sugano, N. Subchondral fracture begins from the bone resorption area in osteonecrosis of the
femoral head: A micro-computerised tomography study. Int. Orthop. 2018, 42, 1479–1484. [CrossRef]
3. Yu, X.; Zhang, D.; Chen, X.; Yang, J.; Shi, L.; Pang, Q. Effectiveness of various hip preservation treatments for non-traumatic
osteonecrosis of the femoral head: A network meta-analysis of randomized controlled trials. J. Orthop. Sci. 2018, 23, 356–364.
[CrossRef]
4. Wang, C.; Meng, H.; Wang, Y.; Zhao, B.; Zhao, C.; Sun, W.; Zhu, Y.; Han, B.; Yuan, X.; Liu, R.; et al. Analysis of early stage
osteonecrosis of the human femoral head and the mechanism of femoral head collapse. Int. J. Biol. Sci. 2018, 14, 156–164.
[CrossRef]
5. Kaneko, S.; Takegami, Y.; Seki, T.; Fukushima, W.; Sakai, T.; Ando, W.; Ishiguro, N.; Sugano, N. Surgery trends for osteonecrosis of
the femoral head: A fifteen-year multi-centre study in Japan. Int. Orthop. 2020, 44, 761–769. [CrossRef]
6. Aigner, N.; Schneider, W.; Eberl, V.; Knahr, K. Core decompression in early stages of femoral head osteonecrosis–an MRI-controlled
study. Int. Orthop. 2002, 26, 31–35. [CrossRef]
7. Bozic, K.J.; Zurakowski, D.; Thornhill, T.S. Survivorship analysis of hips treated with core decompression for nontraumatic
osteonecrosis of the femoral head. J. Bone Jt. Surg. 1999, 81, 200–209. [CrossRef]
8. Calori, G.M.; Mazza, E.; Colombo, A.; Mazzola, S.; Colombo, M. Core decompression and biotechnologies in the treatment of
avascular necrosis of the femoral head. EFORT Open Rev. 2017, 2, 41–50. [CrossRef]
9. Andriolo, L.; Merli, G.; Tobar, C.; Altamura, S.A.; Kon, E.; Filardo, G. Regenerative therapies increase survivorship of avascular
necrosis of the femoral head: A systematic review and meta-analysis. Int. Orthop. 2018, 42, 1689–1704. [CrossRef]
10. Brennan, M.A.; Renaud, A.; Amiaud, J.; Rojewski, M.T.; Schrezenmeier, H.; Heymann, D.; Trichet, V.; Layrolle, P. Pre-clinical
studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate. Stem Cell Res. Ther. 2014, 5,
114. [CrossRef]
11. Zhao, D.; Cui, D.; Wang, B.; Tian, F.; Guo, L.; Yang, L.; Liu, B.; Yu, X. Treatment of early stage osteonecrosis of the femoral head
with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 2012, 50, 325–330. [CrossRef]
12. Sensebé, L.; Bourin, P.; Tarte, K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum. Gene Ther.
2011, 22, 19–26. [CrossRef] [PubMed]
J. Clin. Med. 2021, 10, 508 14 of 14
13. Veronesi, E.; Murgia, A.; Caselli, A.; Grisendi, G.; Piccinno, M.S.; Rasini, V.; Giordano, R.; Montemurro, T.; Bourin, P.; Sensebe,
L.; et al. Transportation conditions for prompt use of ex vivo expanded and freshly harvested clinical-grade bone marrow
mesenchymal stromal/stem cells for bone regeneration. Tissue Eng. Part C Methods 2014, 20, 239–251. [CrossRef] [PubMed]
14. Gomez-Barrena, E.; Padilla-Eguiluz, N.G.; Avendano-Sola, C.; Payares-Herrera, C.; Velasco-Iglesias, A.; Torres, F.; Rosset, P.;
Gebhard, F.; Baldini, N.; Rubio-Suarez, J.C.; et al. A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two
Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after
Long Bone Fractures: Study Protocol. Stem Cells Int. 2018, 2018, 6025918. [CrossRef] [PubMed]
15. Gomez-Barrena, E.; Padilla-Eguiluz, N.; Rosset, P.; Gebhard, F.; Hernigou, P.; Baldini, N.; Rouard, H.; Sensebe, L.; Gonzalo-
Daganzo, R.M.; Giordano, R.; et al. Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to
treat long bone non-unions. Injury 2020, 51 (Suppl. 1), S63–S73. [CrossRef]
16. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz,
E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy 2006, 8, 315–317. [CrossRef]
17. Jensen, M.P.; Chen, C.; Brugger, A.M. Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical
trials of postoperative pain. J. Pain 2003, 4, 407–414. [CrossRef]
18. Gómez-Barrena, E.; Rosset, P.; Gebhard, F.; Hernigou, P.; Baldini, N.; Rouard, H.; Sensebé, L.; Gonzalo-Daganzo, R.M.; Giordano,
R.; Padilla-Eguiluz, N.; et al. Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded,
bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric,
non-comparative trial. Biomaterials 2019, 196, 100–108. [CrossRef]
19. Hernigou, P.; Trousselier, M.; Roubineau, F.; Bouthors, C.; Chevallier, N.; Rouard, H.; Flouzat-Lachaniette, C.H. Stem Cell Therapy
for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress. Clin. Orthop. Surg. 2016, 8, 1–8. [CrossRef]
20. Xu, S.; Zhang, L.; Jin, H.; Shan, L.; Zhou, L.; Xiao, L.; Tong, P. Autologous Stem Cells Combined Core Decompression for
Treatment of Avascular Necrosis of the Femoral Head: A Systematic Meta-Analysis. Biomed. Res. Int. 2017, 2017, 6136205.
[CrossRef]
21. Papakostidis, C.; Tosounidis, T.H.; Jones, E.; Giannoudis, P.V. The role of “cell therapy” in osteonecrosis of the femoral head. A
systematic review of the literature and meta-analysis of 7 studies. Acta Orthop. 2016, 87, 72–78. [CrossRef] [PubMed]
22. Hernigou, P.; Beaujean, F.; Lambotte, J.C. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-
induced osteonecrosis. J. Bone Jt. Surg. 1999, 81, 349–355. [CrossRef]
23. Mao, Q.; Jin, H.; Liao, F.; Xiao, L.; Chen, D.; Tong, P. The efficacy of targeted intraarterial delivery of concentrated autologous
bone marrow containing mononuclear cells in the treatment of osteonecrosis of the femoral head: A five year follow-up study.
Bone 2013, 57, 509–516. [CrossRef] [PubMed]
24. Mao, Q.; Wang, W.; Xu, T.; Zhang, S.; Xiao, L.; Chen, D.; Jin, H.; Tong, P. Combination treatment of biomechanical support
and targeted intra-arterial infusion of peripheral blood stem cells mobilized by granulocyte-colony stimulating factor for the
osteonecrosis of the femoral head: A randomized controlled clinical trial. J. Bone Miner. Res. 2015, 30, 647–656. [CrossRef]
25. Min, B.W.; Song, K.S.; Cho, C.H.; Lee, S.M.; Lee, K.J. Untreated asymptomatic hips in patients with osteonecrosis of the femoral
head. Clin. Orthop. Relat. Res. 2008, 466, 1087–1092. [CrossRef]
26. Koo, K.H.; Kim, R.; Ko, G.H.; Song, H.R.; Jeong, S.T.; Cho, S.H. Preventing collapse in early osteonecrosis of the femoral head. A
randomised clinical trial of core decompression. J. Bone Jt. Surg. 1995, 77, 870–874. [CrossRef]
27. Cruz-Pardos, A.; Garcia-Rey, E.; Ortega-Chamarro, J.A.; Duran-Manrique, D.; Gomez-Barrena, E. Mid-term comparative outcomes
of autologous bone-marrow concentration to treat osteonecrosis of the femoral head in standard practice. Hip Int. 2016, 26,
432–437. [CrossRef]
28. Gangji, V.; De Maertelaer, V.; Hauzeur, J.P. Autologous bone marrow cell implantation in the treatment of non-traumatic
osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone 2011, 49, 1005–1009. [CrossRef]
29. Sen, R.K.; Tripathy, S.K.; Aggarwal, S.; Marwaha, N.; Sharma, R.R.; Khandelwal, N. Early results of core decompression and
autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: A randomized control study. J. Arthroplast.
2012, 27, 679–686. [CrossRef]
30. Tabatabaee, R.M.; Saberi, S.; Parvizi, J.; Mortazavi, S.M.; Farzan, M. Combining Concentrated Autologous Bone Marrow Stem
Cells Injection with Core Decompression Improves Outcome for Patients with Early-Stage Osteonecrosis of the Femoral Head: A
Comparative Study. J. Arthroplast. 2015, 30, 11–15. [CrossRef]
31. Aoyama, T.; Goto, K.; Kakinoki, R.; Ikeguchi, R.; Ueda, M.; Kasai, Y.; Maekawa, T.; Tada, H.; Teramukai, S.; Nakamura, T.; et al.
An exploratory clinical trial for idiopathic osteonecrosis of femoral head by cultured autologous multipotent mesenchymal
stromal cells augmented with vascularized bone grafts. Tissue Eng. Part B Rev. 2014, 20, 233–242. [CrossRef] [PubMed]
32. Mao, L.; Jiang, P.; Lei, X.; Ni, C.; Zhang, Y.; Zhang, B.; Zheng, Q.; Li, D. Efficacy and safety of stem cell therapy for the early-stage
osteonecrosis of femoral head: A systematic review and meta-analysis of randomized controlled trials. Stem Cell Res. Ther. 2020,
11, 445. [CrossRef] [PubMed]
33. Hernigou, P.; Poignard, A.; Beaujean, F.; Rouard, H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of
the number and concentration of progenitor cells. J. Bone Jt. Surg. 2005, 87, 1430–1437. [CrossRef]
